Morphological classification system of hair regrowth patterns in alopecia areata patches: DIMT classification

Alopecia areata: What's new in the diagnosis and treatment with JAK inhibitors?

Alopecia areata (AA) affects individuals of all ages and is intractable in severe relapsing cases. Dermatologists and other healthcare providers should consider AA in the medical context and prioritize treatment. Several randomized controlled clinical studies on Janus kinase (JAK) inhibitors with different specificities for the treatment of AA are ongoing. These studies have encouraged us to appreciate the importance of a definitive diagnosis and accurate evaluation of AA before and during treatment. Following our previous review article in 2017, here we provide the second part of this two-review series on the recent progress in the multidisciplinary approaches to AA from more than 1800 articles published between July 2016 and December 2022. This review focuses on the evaluation, diagnosis, and treatment of AA. We also provide the latest information on the safety and efficacy of JAK inhibitors for the treatment of AA and describe their mechanisms of action.

Targetoid Hair Regrowth Pattern in Alopecia Areata: A Case Series

Alopecia areata (AA) is an autoimmune disorder leading to nonscarring hair loss of the scalp and/or body. Atypical hair regrowth in AA is considered a rare phenomenon. Many paradoxical forms of hair regrowth have been described in AA. Targetoid hair regrowth pattern in AA was first described in 1988. Here, we report three cases wherein this pattern of hair regrowth was seen.